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Comparison of the Hepatic Effects of
Nafenopin and WY-14, 643 on Peroxisome
Proliferation and Cell Replication in the Rat
and Syrian Hamster
by Brian G. Lake1, John G. Evans1, Morag E. Cunninghame,1
and Roger J. Price1
Male Sprague-Dawley rats were fed control diet or diet containing 0.05% nafenopin (NAF) or
0.025% WY-14,643 (WY) and male Syrian hamsters were fed control diet or diet containing 0.25%
NAF or 0.025% WY for periods of 1, 15, 40, and 60 weeks. Both NAF and WY produced a sustained
increase in liver weight and induction of peroxisomal fatty acid n-oxidation in the rat and
Syrian hamster. Replicative DNA synthesis was studied by implanting osmotic pumps contain-
ing 13HI thymidine during weeks 0-1, 14-15, 39-40, and 59-60. Cell replication, determined either
as the hepatocyte labelling index or by incorporation of radioactivity into liver whole
homogenate DNA, was increased in rats given NAF and WY for 1 week. However, only WY pro-
duced a sustained increased in cell replication after 15-60 weeks. After 40 weeks, liver nodules
and tumors were present in WY-treated rats, and these lesions were observed in all WY-treated
and some NAF-treated rats after 60 weeks. In contrast to the rat, no marked effect on replica-
tive DNA synthesis and no liver nodules and tumors were observed in Syrian hamsters given
NAF and WY for up to 60 weeks. The rat study demonstrates that liver tumors are produced
more rapidly by doses of peroxisome proliferators that produce a sustained stimulation of cell
replication, whereas the hamster study suggests that species differences may exist in both per-
oxisome proliferator-induced cell replication and liver tumor formation.
Introduction
A wide variety of compounds including herbicides,
plasticizers, industrial chemicals, natural products,
food flavors, and hypolipidemic and other types of
therapeutic agents have been found to enlarge the
liver, cause hepatic peroxisome proliferation, and
induce peroxisomal and microsomal fatty acid oxidizing
enzyme activities in rats and mice (1-5). Although per-
oxisome proliferators are not mutagenic in various
short-term tests and do not appear to bind covalently
to hepatic DNA after in vivo administration (6-8), sev-
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eral of these compounds have been shown to increase
the incidence ofliver tumors in rats and mice (1,2,9,10).
Indeed, Reddy and co-workers have suggested that
peroxisome proliferators constitute a novel class of
chemical carcinogens (10).
Because peroxisome proliferators appear to be
nongenotoxic carcinogens, it has been suggested that
liver tumor formation arises from a sustained "oxida-
tive stress" to the hepatocytes due to an imbalance in
the production and degradation of peroxisomal hydro-
gen peroxide (2,6-9). This imbalance is due to the fact
that peroxisome proliferators markedly stimulate
enzymes of the peroxisomal fatty acid f-oxidation
cycle (which generate hydrogen peroxide), whereas
only a small increase is observed in catalase activity,
and selenium-dependent glutathione peroxidase activi-
ty is normally inhibited by these chemicals (7,8,11,12).
Although some evidence has been obtained for the
oxidative stress hypothesis (7,8), other workers have
suggested that peroxisome proliferator-induced hepa-
tocarcinogenicity may be due to alternative mecha-
nisms including the sustained stimulation ofreplicativeLAKE ETAL.
DNA synthesis and the promotion of spontaneously
formed preneoplastic liver lesions (13,14).
Peroxisome proliferator-induced liver enlargement
in rodents is due to both hepatocyte hypertrophy and
hyperplasia (2-4). In addition to the initial burst of
hepatocyte replication observed in the first few days of
treatment with peroxisome proliferators, in some stud-
ies a sustained stimulation of hepatocyte cell replica-
tion has been observed (13, 15-18).
The purpose of this study was to further investigate
the relationships between hepatic peroxisome prolifer-
ation, cell replication, and liver tumor formation in the
rat and Syrian hamster. The Syrian hamster was
selected because it is less responsive than the rat to a
number ofperoxisome proliferators including clobuzarit
(19), clofibrate (20), di-(2-ethylhexyl) phthalate (20), LY
171883 (21), and nafenopin (22). In addition, there is a
paucity ofinformation on the effects ofperoxisome pro-
liferators on hepatic cell replication and tumor forma-
tion in the Syrian hamster. The two peroxisome prolif-
erators (for structures see Fig. 1) used in this study
were nafenopin (NAF; 2-methyl-2-[p-(1,2,3,4-tetrahy-
dro-1-naphthyl)phenoxy]propionic acid) and Wy-14,643
(WY; [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic
acid. Both these compounds have been previously
shown toproduce liver tumors in the rat and mouse (2).
Materials and Methods
Chemicals
Enzyme cofactors, etc., were purchased from Sigma
Chemical Co. Ltd. (Poole, Dorset, UK) and Wy-14,643
was purchased from Chemsyn Science Laboratories
(Lenexa, KS). Nafenopin (Su 13,437) was the generous
gift of Ciba-Geigy Ltd. (Basel, Switzerland). Alzet
osmotic pumps were obtained from Charles River UK
Ltd. (Margate, Kent, UK) and [methyl-3H]thymidine
(79-85 mCi/mmole, 1.0 and 3.0 mCi/mL) was obtained
from Amersham International, plc (Little Chalfont,
Bucks, UK).
Animals and Treatment
Male Sprague-Dawley rats (4 weeks old) were pur-
chased from Harlan Olac Ltd. (Bicester, Oxon, UK)
and male MB strain Syrian hamsters (4 weeks old)
from Consort Ltd. (Hovewood End, Hereford, UK).
Animals were allowed free access to R and M No. 1
(rats diets) and R and M No. 3 (hamsters) diets (Special
Diet Services, Witham, Essex, UK) and water. The
animals were housed in mesh -floored cages in rooms
maintained at 22 ± 3°C with a relative humidity of 40-
70%. After acclimatizing to these conditions for 2
weeks, rats were fed control diet or diet containing
0.05% NAF or 0.025% WY, and hamsters were fed con-
trol diet or diet containing 0.025% NAF or 0.075% WY.
The compounds were administered for periods of
1,15,40, and 60 weeks. Animals were killed by exsan-
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FIGURE 1. Structures ofnafenopin and Wy-14,643.
guination under diethyl ether anesthesia, and the liv-
ers were immediately excised for biochemical and mor-
phological studies.
Replicative DNA Synthesis
Animals were anesthetised with sodium pentobarbi-
tone (60 mg/kg, ip) before subcutaneous implantation of
7-day Alzet osmotic pumps containing [3H] thymidine.
Osmotic pumps for rats (model 2ML1) and hamstes
(model 2001) contained 2.0 and 0.6 mCi of [3H] thymi-
dine, respectively. Sections of liver and upper small
intestine (to confirm pump efficiency) were dipped in
liquid photographic emulsion and exposed in the dark
at 4°C for 10 weeks. After processing, the hepatocyte
labelling index (i.e., percentage of the nuclei undergo-
ing replicative DNA synthesis) was assessed by micro-
scopic examination of at least 1000 nuclei in random
fields from the left lobe of the liver. Hepatic whole
homogenate DNA content was determined in liver
homogenates (see below) by the method of Setaro and
Morley (23), and radioactivity incorporated into DNA
was determined by scintillation counting.
Biochemical and Morphological
Investigations
Whole liver homogenates (rat 0.25g and hamster
0.1g fresh tissue/mL) were prepared in 0.154 M KCI
containing 50 mM Tris-HCl, pH 7.4, using a Potter-
type, Teflon-glass, motor-driven homogenizer (A. H.
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Thomas Co., Philadelphia, PA). When animals had
large liver nodules or tumors, samples ofthe surround-
ing host tissue were selected for homogenization.
Liver whole homogenates were assayed for cyanide-
insensitive palmitoyl-CoA oxidation (22) and protein
content (24).
Liver slices were fixed in neutral buffered formalin.
Paraffin sections were cut at 5 gm, stained with hema-
toxylin and eosin, and examined by light microscopy.
Statistical Analysis
Statistical evaluation ofdata was performed by one-
way analysis ofvariance. Comparisons between means
were made using the least significant difference test.
Results
Effect on Liver Weight and
Peroxisomal FattyAcid 3-Oxidation
Treatment of rats with diets containing 0.05% NAF
or 0.025% WY markedly increased relative liver weight
after 1, 15, 40, and 60 weeks of treatment (Fig. 2A).
Relative liverweight was also significantly increased in
Syrian hamsters fed diets containing either 0.25% NAF
or 0.025% WY (Fig. 2B). In both species, WY produced
a greater increase in relative liver weight than NAF
after 15,40 and 60 weeks oftreatment.
Peroxisomal (whole homogenate cyanide-insensitive
palmitoyl-CoA oxidation) fatty acid n-oxidation was
markedly induced by both NAF and WY administra-
tion to the rat (Fig. 3A) and Syrian hamster (Fig. 3B)
at all time points. Although enzyme activity (nmole/
min/mg protein) was induced to similar levels in both
species (Fig. 3A,B), the magnitude of induction was
greater in the rat than in the Syrian hamster owing to
a 2.3-fold higher basal level of enzyme activity in the
hamster. Mean values for induction of palmitoyl-CoA
oxidation over the 1-60 week treatment period by
NAF and WY were 1180 and 1110% of control for the
rat and 415 and 590% of control for the Syrian ham-
ster, respectively.
Effect on Replicative DNA Synthesis
Replicative DNA synthesis was determined over
study weeks 0-1, 14-15, 39-40 and 59-60 with 7-day
Alzet osmotic pumps containing [3H] thymidine. After
1 week, replicative DNA synthesis as assessed by [3H]
thymidine incorporation into hepatic DNA, was signifi-
cantly increased in rats given both NAF and WY (Fig.
4A). However, after 15, 40, and 60 weeks oftreatment,
hepatic DNA radioactivity levels were still significant-
ly increased by WY, whereas NAF had no effect. In
contrast, in the Syrian hamster, neither compound pro-
duced a significant increase in hepatic DNA radioactiv-
ity levels at any time point (Fig4B).
Replicative DNA synthesis, as assessed by the hepa-
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FIGURE 2. Effect of dietary administration of nafenopin and WY for
1, 15, 40, and 60 weeks on relative liver weight in the rat (A) and
Syrian hamster (B). Results are presented as means + SEM (n =
5-7). Values significantly different from controls (**) p < 0.01;
(***) p < 0.001.
tocyte labelling index (LI), was significantly increased
in the rat to 580 and 535% of control levels by treat-
ment with NAF and WY, respectively, for 1 week (Fig
5A). However, after 15 and 40 weeks of treatment,
only WY produced a significant increase in hepatocyte
LI values to 395 and 855% of control, respectively. In
contrast to the rat, neither compound produced a sig-
nificant increase in hepatocyte LI values in the Syrian
hamster at any time point examined (Fig. 5B).
Effect on Liver Morphology
No macroscopic liver lesions (i.e., liver nodules or
tumors) were observed in either NAF- or WY- treated
rats after 1 and 15 weeks and in control animals after
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FIGURE 3. Effect of dietary administration of nafenopin and VVY for
1, 15, 40, and 60 weeks on cyanide-insensitive palmitoyl-CoA oxi-
dation in the rat (A) and Syrian hamster (B). Results are present-
ed as means ± SEM (n = 5-7). Values significantly different from
controls (***) p < 0.001.
1, 15, 40, and 60 weeks of treatment (Table 1). How-
ever, macroscopic liver lesions were present in all
WY-treated rats after 40 and 60 weeks and in 73% of
NAF-treated rats after 60 weeks. In contrast to the
rat, no macroscopic liver lesions were observed in con-
trol, NAF-, and WY-treated Syrian hamsters at any
time point (Table 1).
Histological examination of liver sections from con-
trol and NAF-treated rats after 40 weeks revealed no
abnormalities, whereas basophilic foci and nodules
were observed in liver sections from all WY-treated
rats. In addition, areas ofadenoma and carcinoma were
identified in liver sections from some WY-treated rats.
No abnormalities were observed in liver sections from
control rats after 60 weeks, whereas liver sections
sented as means ± SEM (n = 5-7). Values significantly different
from controls (**) p < 0.01; (***) p< 0.001.
from all WY-treated and most NAF- treated rats con-
tained basophilic foci and nodules together with areas
ofadenoma and carcinoma.
Histological examination of liver sections from con-
trol hamsters after 40 and 60 weeks revealed no abnor-
malities, whereas slight cellular hypertrophy of peri-
portal hepatocytes was observed in liver sections from
NAF- and WY-treated hamsters. No peroxisome pro-
liferator-induced liver foci, nodules, adenomas or carci-
nomas were observed in this species. However, after
60 weeks in WY-treated but not in NAF-treated ham-
sters, some fatty vacuolation ofperiportal hepatocytes
and slight bile duct proliferation was observed.
Discussion
These results demonstrate that the chronic adminis-
tration of both NAF and WY results in a sustained
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FIGURE 5. Effect ofdietary administration of nafenopin and WY for
1, 15, and 40 weeks on hepatocyte labelling index in the rat (A)
and Syrian hamster (B). Results are presented as means ± SEM
(n = 5-7). Values significantly different from controls (***) p <
0.001.
increase in liver weight and induction ofhepatic perox-
isome proliferation (as assessed by palmitoyl-CoA oxi-
dation) in the rat and Syrian hamster. Although these
data confirm the results of previous rat studies (1-4,
12,13) they extend the findings of previous hamster
studies (19-22,25,26) where peroxisome proliferators
were administered for much shorter periods ranging
from 2 to 6 weeks.
In the rat, both peroxisome proliferators produced a
similar magnitude of induction of hepatic peroxisome
proliferation, but had different effects on hepatic
replicative DNA synthesis. Although both compounds
stimulated hepatic replicative DNA synthesis (assessed
either as the hepatocyte labelling index or as incorpo-
ration of [3H] thymidine into whole homogenate DNA)
during the first week oftreatment, only WY produced
a sustained stimulation throughout the remainder of
the 60 weeks of administration. In addition, WY pro-
duced liver nodules, adenomas, and carcinomas within
40 weeks, whereas these liver lesions were only
observed after 60 weeks of NAF administration. As
such, these results are in agreement with those of a
previous 1 year study conducted in F344 rats with di-
(2-ethylhexyl)phthalate and WY (13). Although both
compounds produced a similar magnitude of induction
of peroxisome proliferation, only WY produce a sus-
tained stimulation of cell replication and liver tumors
after 1 year oftreatment. Thus, from the results ofthe
1-year study and the present study, a similar magni-
tude ofinduction ofhepatic peroxisome proliferation in
the rat does not necessarily result in a similar time
course of liver tumor formation. Rather, liver tumors
appear to be produced more rapidly by doses ofperoxi-
some proliferators that produce a sustained stimula-
tion ofcell replication in this species.
In agreement with previous studies on species dif-
ferences in hepatic peroxisome proliferation (19-22),
the magnitude of induction ofpalmitoyl-CoA oxidation
was greater in the rat than in the Syrian hamster.
However, although hepatic peroxisome proliferation
was observed in both the rat and Syrian hamster,
species differences in the hepatic effects of NAF and
WY were also apparent. For example, neither com-
pound significantly increased replicative DNA synthe-
sis in hamster liver at any ofthe time points examined.
In a comparative study of acute hyperplasia induced
by methylclofenapate, a potent peroxisome prolifera-
tor and hepatocarcinogen (2,3), Styles and co-workers
(27) observed a marked effect in rat and mouse liver,
but only a small effect in Syrian hamster hepatocytes.
Clearly, the Syrian hamster is much less susceptible
than the rat to peroxisome proliferator-induced hyper-
plasia, and in the present study morpholocial examina-
tion ofliver sections indicated that the increase in liver
Table 1. Macroscopic lesions in the livers ofrats and Syrian hamsters treated with nafenopin (NAF) and Wy-14,643 (WY).
Rata Syrian hamster
Weeks of 0.05% 0.025% 0.25% 0.025%
treatment Control NAF WY Control NAF WY
1 and 15 0(6)b 0(6) 0(6) 0(6) 0(6) 0(6)
40 0(6) 0(6) 6(6) 0(6) 0(6) 0(6)
60 0(8) 8(11) 12(12) 0(9) 0(8) 0(8)
aLesions include small nodules and liver tumors.
bFigures in parentheses are the numbers ofanimals examined.
S x
_aD
E
.J .0I
245
1246 LAKE ETAL.
weight was primarily due to hepatocyte hypertrophy.
A second important species difference observed in
this study is that, although both NAF and WY pro-
duced liver nodules, adenomas and carcinomas in the
rat, no such peroxisome proliferator-induced liver
lesions were observed after 60 weeks of treatment in
the Syrian hamster. This observation suggests that the
Syrian hamster is more resistant than the rat to peroxi-
some proliferator-induced hepatocarcinogenicity and,
indeed, that species differences may exist in both hepat-
icperoxisome proliferation and livertumorformation.
Several hypotheses have been proposed to account
for the formation ofliver tumors by peroxisome prolif-
erators in rats and mice (2,6-9,13-14). Ifthese hypothe-
ses are combined, a role for increased cell replication in
peroxisome proliferator-induced hepatocarcinogenicity
may be identified. For example, if hepatocytes are
transformed either by oxidative stress-induced dam-
age (2,6-9) or spontaneously (14), such initiated cells
could be promoted into liver tumors by enhanced cell
replication (13). Certainly the present rat study with
NAF and WY supports the concept that liver tumors
are produced more rapidly by doses ofperoxisome pro-
liferators that produce a sustained stimulation of cell
replication. In contrast, no marked induction ofreplica-
tive DNA synthesis and no liver tumors were
observed in Syrian hamsters given five times and the
same dietary level of NAF and WY, respectively.
Because hepatic peroxisome proliferation but not cell
replication may be observed in the Syrian hamster,
this species may be suitable for further studies aimed
at establishing the respective roles ofperoxisome pro-
liferator-induced oxidative stress and enhanced cell
replication in the hepatocarcinogenicity of peroxisome
proliferators. Finally, in keeping with our previous
suggestions (20,22), because the Syrian hamster is less
responsive than the rat to such chemicals, appropriate
bioassays conducted in the Syrian hamster may pro-
vide valuable data to assist in the assessment of the
hazard, if any, of hepatocarcinogenic rodent peroxi-
some proliferators to man.
This work forms part ofa research project sponsored by the U.K.
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